Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD

REGENERON PHARMACEUTICALS, INC.

2024-Q2 EPS reported $18.68 revenue$6,692,100,000

Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).
Dupixent global net sales up 27% to $3.56B; EU approved for COPD; FDA decision expected Sept 27, 2024.
EYLEA HD/EYLEA U.S. sales $1.53B (+2%), including $304M from EYLEA HD.
Libtayo global net sales up 42% to $297M; pipeline progress in obesity, gene therapy, oncology.
New $3B share repurchase authorization; $601M repurchased in Q2; 2024 guidance updated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.